Literature DB >> 29400123

Increased adhesion molecule levels in systemic lupus erythematosus: relationships with severity of illness, autoimmunity, metabolic syndrome and cortisol levels.

L F da Rosa Franchi Santos1, N P Stadtlober1, L G Costa Dall'Aqua1, B M Scavuzzi2, P M Guimarães2, T Flauzino2, M A Batisti Lozovoy3, T V Mayumi Iriyoda4, E M Vissoci Reiche3, I Dichi5, M Maes6, A Colado Simão3.   

Abstract

Background This study was performed to assess adhesion molecules in systemic lupus erythematosus (SLE). Methods This case-control study examined 126 SLE patients and 48 healthy individuals. Blood levels of six adhesion molecules, cortisol, nuclear autoantibody (ANA) and anti-double stranded DNA (anti-dsDNA) titers were measured, while disease activity was assessed using the SLE Disease Activity Index (SLEDAI) score. Results Platelet endothelial cell adhesion molecule 1 (PECAM-1), vascular cell adhesion molecule 1 (VCAM-1), E-selectin, P-selectin, and plasminogen activator inhibitor type-1 (PAI-1) were significantly higher in SLE patients than in controls. Binary logistic regression analysis showed that PECAM-1 and PAI-1 predicted SLE with a sensitivity of 86.5% and a specificity of 81.3%. ANA titers were significantly and positively associated with PECAM-1, VCAM-1, E-selectin, and PAI-1, whereas there were no associations between anti-dsDNA titers and adhesion molecules. Cortisol was negatively associated with PCAM-1 and ICAM-1. There were significant associations between metabolic syndrome (MetS) and E-selectin and PAI-1. 14.8% of the variance in the SLEDAI score was explained by the regression on PECAM-1 and MetS. Conclusions Our data show that adhesion molecules, especially PECAM-1, are significantly associated with SLE and disease activity, suggesting that they play a role in SLE pathophysiology. While MetS, ANA titers and cortisol levels modulate adhesion molecule levels, these associations do not explain the increased levels of adhesion molecules in SLE. Increased levels of adhesion molecules are new drug targets in SLE.

Entities:  

Keywords:  ANA; Systemic lupus erythematosus; adhesion molecules; body mass index; cortisol; metabolic syndrome

Mesh:

Substances:

Year:  2018        PMID: 29400123     DOI: 10.1177/0961203317723716

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  12 in total

1.  Increased lipid and protein oxidation and lowered anti-oxidant defenses in systemic lupus erythematosus are associated with severity of illness, autoimmunity, increased adhesion molecules, and Th1 and Th17 immune shift.

Authors:  Bruna Miglioranza Scavuzzi; Andréa Name Colado Simão; Tatiana Mayumi Veiga Iriyoda; Marcell Alysson Batisti Lozovoy; Nicole Perugini Stadtlober; Lorena Flor da Rosa Franchi Santos; Tamires Flauzino; Fabiano Aparecido de Medeiros; Marcelo Cândido de Sá; Luana Consentin; Edna Maria Vissoci Reiche; Michael Maes; Isaias Dichi
Journal:  Immunol Res       Date:  2018-02       Impact factor: 2.829

Review 2.  Endothelial cells: potential novel regulators of renal inflammation.

Authors:  Jim C Oates; Dayvia L Russell; Justin P Van Beusecum
Journal:  Am J Physiol Renal Physiol       Date:  2022-02-07

Review 3.  Cardiovascular disease risk and pathogenesis in systemic lupus erythematosus.

Authors:  Christopher B Oliveira; Mariana J Kaplan
Journal:  Semin Immunopathol       Date:  2022-03-30       Impact factor: 11.759

Review 4.  Adhesion molecules: a way to understand lupus.

Authors:  Karolina Nowak; Olga Gumkowska-Sroka; Przemysław Kotyla
Journal:  Reumatologia       Date:  2022-05-18

5.  Cell adhesion molecules, plasminogen activator inhibitor type 1, and metabolic syndrome in patients with psoriasis.

Authors:  Guilherme Gomes Teixeira; Naiara Lourenço Mari; Jaqueline Costa Castardo de Paula; Camila Cataldi de Alcantara; Tamires Flauzino; Marcell Alysson Batisti Lozovoy; Ligia Márcia Mário Martin; Edna Maria Vissoci Reiche; Michael Maes; Isaias Dichi; Andréa Name Colado Simão
Journal:  Clin Exp Med       Date:  2019-11-22       Impact factor: 3.984

Review 6.  Redox Control of Integrin-Mediated Hepatic Inflammation in Systemic Autoimmunity.

Authors:  Akshay Patel; Andras Perl
Journal:  Antioxid Redox Signal       Date:  2021-07-07       Impact factor: 7.468

7.  Comprehensive aptamer-based screening identifies a spectrum of urinary biomarkers of lupus nephritis across ethnicities.

Authors:  Samantha Stanley; Kamala Vanarsa; Samar Soliman; Deena Habazi; Claudia Pedroza; Gabriel Gidley; Ting Zhang; Shree Mohan; Evan Der; Hemant Suryawanshi; Thomas Tuschl; Jill Buyon; Chaim Putterman; Chi Chiu Mok; Michelle Petri; Ramesh Saxena; Chandra Mohan
Journal:  Nat Commun       Date:  2020-05-04       Impact factor: 14.919

8.  Disease activity index is associated with subclinical atherosclerosis in childhood-onset systemic lupus erythematosus.

Authors:  Priscila B S Medeiros; Roberta G Salomão; Sara R Teixeira; Diane M Rassi; Luciana Rodrigues; Davi C Aragon; Priscila G Fassini; Fábio V Ued; Rita C Tostes; Jacqueline P Monteiro; Virgínia P L Ferriani; Luciana M de Carvalho
Journal:  Pediatr Rheumatol Online J       Date:  2021-03-20       Impact factor: 3.054

9.  Association of Plasminogen Activator Inhibitor 1 (PAI-1) 4G/5G Polymorphism and Susceptibility to SLE in Egyptian Children and Adolescents: A Multicenter Study.

Authors:  Aly A Yousef; Faisal Y Mohamed; Naglaa F Boraey; Nagwa E Akeel; Attia A Soliman; Nevin M Waked; Mustafa I A Hashem; Hassan Shehata; Dalia S Fahmy; Ali Ismael; Lamya M Ibrahim; Mohamed A M Ibrahim; Hanan F Salem; Sherif M Yousry; Sherif F Osman; Rania A Fouad; Eman T Enan; Mohammed A Attia; Mona R Afify; Nancy M S Zeidan; Mohamed Nashat
Journal:  J Inflamm Res       Date:  2020-12-14

10.  TRIM27 contributes to glomerular endothelial cell injury in lupus nephritis by mediating the FoxO1 signaling pathway.

Authors:  Jinxi Liu; Jie Xu; Jie Huang; Cunyang Gu; Qingjuan Liu; Wei Zhang; Fan Gao; Yuexin Tian; Xinyan Miao; Zixuan Zhu; Baiyun Jia; Yu Tian; Lunbi Wu; Hang Zhao; Xiaojuan Feng; Shuxia Liu
Journal:  Lab Invest       Date:  2021-04-14       Impact factor: 5.502

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.